There’s a lot going on underneath the surface with Isracann Biosciences (IPOT.C). A year in review won’t be much, mostly because this company hasn’t been public for a year. Instead, it’s more like a quarter-in-review, as the company only rolled into Atlas Blockchain, going public on the CSE (and OTC exchange as ISCNF) in October of 2019, but what makes this (and them) noteworthy is what they’ve managed to build for themselves in such a short timespan.
On December 17, 2019 Isracann (IPOT.C) announced that it has entered into an Memorandum of Understanding (MOU) for a joint venture (JV) with an additional cannabis farm property in Israel.
Isracann BioSciences (IPOT) is the first pure pot play growing in the Promised Land. You may not think this middle east nation state is a tactical choice when it comes to legal weed, but Israel leads the world in medical cannabis research with some researchers joking they are going to write the Torah of cannabis.
Isracann Biosciences (IPOT.C) got the regulatory nod from the Israeli Land Authority for their land use and facility design, but before they can get started with construction of their phase 1 build-out, they’re going to need permits from the Israeli Settlement Commissioner and the Israeli Ministry of Health, both of which are pending.
Isracann Biosciences (IPOT.C), an Israel-based cannabis play, has engaged the services of LinC by Growing Smart to draw a project roadmap for their proposed 230,000 square foot production facility.
As a general rule, I’m against any company with ‘cann’ or ‘canna’ in its title. You could make a drinking game out of reading the names of cannabis companies and taking a slug of tequila whenever you hit a canna, and you’d be drunktank-ready inside 25 syllables.
A few days ago, I published a story about our friends from HIKU/Tokyo Smoke/Doja/Saxx who, having exited from their last company with a $400m+ acquisition by Canopy Growth Corp (WEED.T), were quietly gathering investors for their next deal, Stately.